134 related articles for article (PubMed ID: 18327857)
1. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding.
Weiner MG; Xie D; Tannen RL
Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):661-70. PubMed ID: 18327857
[TBL] [Abstract][Full Text] [Related]
2. Hormone therapy and coronary heart disease in young women.
Weiner MG; Barnhart K; Xie D; Tannen RL
Menopause; 2008; 15(1):86-93. PubMed ID: 17502840
[TBL] [Abstract][Full Text] [Related]
3. Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the 'prior event rate ratio' to adjust for unmeasured confounding by indication.
Tannen RL; Weiner MG; Xie D
Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):671-85. PubMed ID: 18327852
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
[TBL] [Abstract][Full Text] [Related]
6. Simulation of the Syst-Eur randomized control trial using a primary care electronic medical record was feasible.
Tannen RL; Weiner MG; Marcus SM
J Clin Epidemiol; 2006 Mar; 59(3):254-64. PubMed ID: 16488356
[TBL] [Abstract][Full Text] [Related]
7. [4S [Scandinavian Simvastatin Survival Study]].
Koizumi J; Yoshida I
Nihon Rinsho; 2001 Mar; 59 Suppl 3():410-5. PubMed ID: 11347105
[No Abstract] [Full Text] [Related]
8. A simulation using data from a primary care practice database closely replicated the women's health initiative trial.
Tannen RL; Weiner MG; Xie D; Barnhart K
J Clin Epidemiol; 2007 Jul; 60(7):686-95. PubMed ID: 17573984
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
[TBL] [Abstract][Full Text] [Related]
10. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM
Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959
[TBL] [Abstract][Full Text] [Related]
11. A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone.
Tannen R; Xie D; Wang X; Yu M; Weiner MG
Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):86-97. PubMed ID: 23070833
[TBL] [Abstract][Full Text] [Related]
12. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Holme I; Szarek M; Cater NB; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Larsen ML; Lindahl C; Pedersen TR;
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):315-20. PubMed ID: 19322096
[TBL] [Abstract][Full Text] [Related]
13. An application of propensity score matching using claims data.
Seeger JD; Williams PL; Walker AM
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):465-76. PubMed ID: 15651087
[TBL] [Abstract][Full Text] [Related]
14. Statins and cancer risk.
Karp I; Behlouli H; Lelorier J; Pilote L
Am J Med; 2008 Apr; 121(4):302-9. PubMed ID: 18374689
[TBL] [Abstract][Full Text] [Related]
15. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores.
Eng PM; Seeger JD; Loughlin J; Clifford CR; Mentor S; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):297-305. PubMed ID: 18215000
[TBL] [Abstract][Full Text] [Related]
16. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Strandberg TE; Holme I; Faergeman O; Kastelein JJ; Lindahl C; Larsen ML; Olsson AG; Pedersen TR; Tikkanen MJ;
Am J Cardiol; 2009 May; 103(10):1381-5. PubMed ID: 19427432
[TBL] [Abstract][Full Text] [Related]
17. A sensitivity analysis using information about measured confounders yielded improved uncertainty assessments for unmeasured confounding.
McCandless LC; Gustafson P; Levy AR
J Clin Epidemiol; 2008 Mar; 61(3):247-55. PubMed ID: 18226747
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.
Kirtane AJ; Gupta A; Iyengar S; Moses JW; Leon MB; Applegate R; Brodie B; Hannan E; Harjai K; Jensen LO; Park SJ; Perry R; Racz M; Saia F; Tu JV; Waksman R; Lansky AJ; Mehran R; Stone GW
Circulation; 2009 Jun; 119(25):3198-206. PubMed ID: 19528338
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin for cardiovascular prevention: too many uncertainties.
Prescrire Int; 2009 Aug; 18(102):176. PubMed ID: 19746571
[TBL] [Abstract][Full Text] [Related]
20. Use of propensity score technique to account for exposure-related covariates: an example and lesson.
Seeger JD; Kurth T; Walker AM
Med Care; 2007 Oct; 45(10 Supl 2):S143-8. PubMed ID: 17909373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
